Reaction

Nasal Obstruction reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,824 reports · 35 co-occurring drugs

As of the last recalculation, Nasal Obstruction appears in 1,824 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is CICLESONIDE (PRR 112.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ciclesonide	125	112.4	113.4
Fluticasone Furoate	59	57.4	57.7
Ipratropium Bromide	122	41.7	41.9
Dextrose	31	27.3	27.4
Dextrose Monohydrate	31	26.9	27.0
Antacid	97	24.6	24.6
Iohexol	17	23.6	23.7
Fluticasone Furoate And Vilanterol Trifenatate	60	19.6	19.7
Fluticasone Propionate And Salmeterol Xinafoate	97	19.4	19.4
Budesonide	95	19.4	19.4
Calcium Carbonate	103	18.5	18.5
Tiotropium Bromide	192	17.8	17.8
Budesonide And Formoterol Fumarate Dihydrate	133	16.8	16.8
Albuterol	138	14.1	14.1
Mepolizumab	57	13.5	13.5
Pantoprazole Sodium In 0.9% Sodium Chloride	65	12.4	12.4
Pantoprazole Sodium Injection	65	12.4	12.4
Nicotine	42	12.1	12.1
Montelukast Sodium	121	12.1	12.1
Palivizumab	15	11.2	11.2
Dupilumab	359	10.3	10.3
Levothyroxine Sodium Anhydrous	82	9.7	9.7
Daratumumab	32	9.3	9.3
Tiotropium Bromide Inhalation Spray	9	9.2	9.2
Mometasone Furoate	33	9.2	9.2
Albuterol Sulfate	203	8.7	8.7
Atorvastatin Calcium, Film Coated	51	8.5	8.5
Omalizumab	61	8.4	8.4
Selexipag	17	7.6	7.6
Montelukast	53	7.4	7.4
Insulin Lispro	63	5.4	5.4
Tenofovir Disoproxil Fumarate Tablets	4	5.3	5.3
Riociguat	15	5.3	5.3
Varenicline Tartrate	27	3.9	3.9
Axicabtagene Ciloleucel	3	3.5	3.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.